During the last session, G1 Therapeutics Inc (NASDAQ:GTHX)’s traded shares were 0.44 million, with the beta value of the company hitting 1.70. At the end of the trading day, the stock’s price was $3.99, reflecting an intraday gain of 3.37% or $0.13. The 52-week high for the GTHX share is $5.00, that puts it down -25.31 from that peak though still a striking 72.93% gain since the share price plummeted to a 52-week low of $1.08. The company’s market capitalization is $208.28M, and the average trade volume was 1.29 million shares over the past three months.
G1 Therapeutics Inc (NASDAQ:GTHX) trade information
G1 Therapeutics Inc (GTHX) registered a 3.37% upside in the last session and has traded in the red over the past 5 sessions. The stock spiked 3.37% in intraday trading to $3.99, hitting a weekly high. The stock’s 5-day price performance is -2.92%, and it has moved by -10.74% in 30 days. Based on these gigs, the overall price performance for the year is 62.20%.
G1 Therapeutics Inc (GTHX) estimates and forecasts
Statistics show that G1 Therapeutics Inc has outperformed its competitors in share price, compared to the industry in which it operates. G1 Therapeutics Inc (GTHX) shares have gone up 193.38% during the last six months, with a year-to-date growth rate more than the industry average at 31.18% against 12.90. In the rating firms’ projections, revenue will decrease -15.30% compared to the previous financial year.
As companies strive to predict their financial trajectories, we turn our attention to the forthcoming financial quarter. Here are the insights gathered from industry analysts. Revenue for the current quarter is expected to be 15.26M as predicted by 5 analyst(s). Meanwhile, a consensus of 5 analyst(s) estimates revenue growth to 16.41M by the end of current fiscal year. As per earnings report from last fiscal year’s results, sales for the corresponding quarters totaled 12.95M and 42.39M respectively. In this case, analysts expect current quarter sales to grow by 17.90% and then drop by -61.30% in the coming quarter.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 18.38%. While earnings are projected to return 28.33% in 2024.
GTHX Dividends
G1 Therapeutics Inc is due to release its next quarterly earnings in May. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
